نتائج البحث

LncRNA Nicotinamide Nucleotide Transhydrogenase-Antisense RNA1 NNT-AS1 in CRC

• Authors : Prof. Nadia M. Hamdy, Ph.D., professor of biochemistry and molecular biology

• Source: LncRNA NNT-AS1/Hsa-miR-485-5p/HSP90 Axis In-silico and Clinical Prospect correlated-to Histologic Grades-based CRC Stratification: A Step Toward ncRNA PrecisionEl-Sheikh NM, Abulsoud AI, Fawzy

تفاصيل العنوان

The Role of HSP90 in Peripheral Vascular Lesions of Diabetic Atherosclerosis (rhsppvlda)

• Source: The Role of HSP90 in Peripheral Vascular Lesions of Diabetic AtherosclerosisDing X, Meng C, Dong H, Zhang S, Zhou H, Tan W, Huang L, He A, Li J, Huang J, Li W, Zou F, Zou M. Extracellular

تفاصيل العنوان

Combined Technology Enhanced Home Exercise Program and Other Non-pharmacological Intervention for Cancer Survivors (TEHEplus)

• Authors : Johns Hopkins University; Oncology Nursing Society

• Source: Effectiveness of the Combined Technology-enhanced Home Exercise Program and Other Non-pharmacological Interventions on Fatigue, Physical Function and Well-being Among Cancer Survivors

تفاصيل العنوان

Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors

• Source: Phase 1/2 Study of Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors

تفاصيل العنوان

Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL

• Source: A Phase 1, Open-label Study of SNX-5422 Added to Ibrutinib in Chronic Lymphocytic Leukemia Subjects With Residual Disease

تفاصيل العنوان

Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy

• Authors : Novartis Pharmaceuticals

• Source: A Phase II Single Arm Study of AUY922 in Patients With Metastatic Pancreatic Adenocarcinoma Who Are Resistant to First Line Chemotherapy

تفاصيل العنوان

Study of SNX-5422 in TP53 Null Cancers

• Source: A Single Arm Study of SNX-5422 in Subjects With TP53 Null Cancers

تفاصيل العنوان

Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors

• Source: A Phase 1, Open-label, Dose-escalation Study of SNX 5422 and Everolimus in Subjects With Neuroendocrine Tumors.

تفاصيل العنوان

Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s)

• Authors : Prof. Nadia M. Hamdy, Ph.D., Professor of biochemistry and molecular biology

• Source: Modulatory Effect of Prodigiosin or Pioglitazone on Tumor Immune Microenvironment and the Crosstalk to Immune-Checkpoint Protein(s)Abdelhamed S, Ogura K, Yokoyama

تفاصيل العنوان

Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors

• Source: A Phase 1, Open-label, Dose-escalation Study of SNX 5422 Plus Carboplatin and Paclitaxel in Subjects With Selected Solid Tumors.

تفاصيل العنوان